Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
3.40
Dollar change
-0.69
Percentage change
-16.87
%
Index- P/E- EPS (ttm)-0.61 Insider Own17.77% Shs Outstand51.93M Perf Week-25.27%
Market Cap177.75M Forward P/E- EPS next Y-0.35 Insider Trans-2.15% Shs Float42.99M Perf Month-14.79%
Income-30.59M PEG- EPS next Q-0.17 Inst Own27.51% Short Float8.34% Perf Quarter41.67%
Sales84.04M P/S2.12 EPS this Y39.64% Inst Trans12.28% Short Ratio2.64 Perf Half Y100.00%
Book/sh0.53 P/B6.40 EPS next Y38.44% ROA-23.18% Short Interest3.59M Perf Year26.39%
Cash/sh1.25 P/C2.72 EPS next 5Y- ROE-84.13% 52W Range1.08 - 6.14 Perf YTD11.48%
Dividend Est.- P/FCF- EPS past 5Y18.38% ROI-44.41% 52W High-44.63% Beta1.71
Dividend TTM- Quick Ratio2.55 Sales past 5Y18.67% Gross Margin91.89% 52W Low214.81% ATR (14)0.41
Dividend Ex-Date- Current Ratio2.94 EPS Y/Y TTM78.79% Oper. Margin-27.16% RSI (14)30.62 Volatility13.01% 10.42%
Employees100 Debt/Eq1.70 Sales Y/Y TTM46.55% Profit Margin-36.40% Recom1.71 Target Price8.40
Option/ShortYes / Yes LT Debt/Eq1.48 EPS Q/Q63.34% Payout- Rel Volume2.01 Prev Close4.09
Sales Surprise-4.83% EPS Surprise-0.96% Sales Q/Q11.82% EarningsMay 01 BMO Avg Volume1.36M Price3.40
SMA20-22.71% SMA50-20.48% SMA20020.31% Trades Volume2,794,137 Change-16.87%
Date Action Analyst Rating Change Price Target Change
Jan-30-23Upgrade JP Morgan Underweight → Neutral $7 → $10
Jan-03-23Reiterated Needham Buy $32 → $31
Nov-04-21Downgrade JP Morgan Neutral → Underweight $20 → $19
Oct-15-21Resumed BTIG Research Buy $51
Sep-30-21Downgrade JP Morgan Overweight → Neutral $24 → $20
Nov-17-20Downgrade Raymond James Strong Buy → Outperform
Jun-26-20Initiated ROTH Capital Buy $55
Jan-21-20Reiterated H.C. Wainwright Buy $72 → $82
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
May-28-24 06:30AM
May-23-24 05:06PM
May-22-24 10:00AM
06:30AM
May-02-24 10:43AM
03:09AM Loading…
03:09AM
May-01-24 11:04PM
05:50PM
09:33AM
07:54AM
07:40AM
06:30AM
06:25AM
Apr-17-24 09:00AM
Apr-11-24 09:15AM
10:30AM Loading…
Apr-04-24 10:30AM
Apr-01-24 04:20PM
Mar-01-24 04:20PM
Feb-29-24 10:21AM
Feb-28-24 11:09PM
07:40AM
06:51AM
06:30AM
Feb-27-24 08:30AM
Feb-15-24 08:30AM
Feb-13-24 08:15AM
Feb-12-24 04:05PM
Jan-08-24 06:45AM
Jan-03-24 05:02PM
09:00AM
04:51PM Loading…
Jan-02-24 04:51PM
Dec-13-23 11:05PM
Dec-05-23 09:26AM
Dec-01-23 04:27PM
Nov-29-23 08:37PM
Nov-02-23 09:46AM
Nov-01-23 11:49PM
09:45AM
06:30AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
Oct-18-23 08:00AM
07:30AM
Oct-16-23 09:00AM
Sep-18-23 07:00AM
Sep-05-23 11:00AM
Sep-01-23 04:15PM
Aug-02-23 07:45AM
06:30AM
Jul-31-23 02:30PM
08:30AM
Jul-27-23 09:42AM
Jul-26-23 09:00AM
Jul-06-23 04:15PM
Jun-04-23 09:17AM
07:13AM
Jun-01-23 04:40PM
May-22-23 04:45PM
May-16-23 07:30AM
May-10-23 07:31AM
May-08-23 06:02AM
May-05-23 06:12AM
May-03-23 02:20PM
07:45AM
06:30AM
May-01-23 05:00PM
Apr-26-23 12:45PM
Apr-18-23 10:16AM
Apr-12-23 12:00PM
Apr-11-23 12:30PM
Mar-02-23 09:55PM
12:01AM
Mar-01-23 07:55AM
06:30AM
Feb-28-23 02:10PM
Feb-22-23 10:00AM
Feb-17-23 07:40AM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-13-23 01:33PM
08:03AM
07:00AM
06:00AM
Feb-09-23 08:00AM
Feb-01-23 04:46PM
Jan-11-23 07:00AM
Jan-09-23 06:30AM
Jan-04-23 11:01AM
06:30AM
Jan-03-23 02:00PM
Dec-07-22 06:04PM
Dec-01-22 11:41PM
Nov-27-22 10:09PM
Nov-23-22 10:30AM
Nov-22-22 04:01PM
Nov-17-22 08:12PM
04:01PM
Nov-03-22 08:17AM
Nov-02-22 10:19AM
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomas Monica R.Chief Legal & People OfficerMay 23 '24Sale4.275,82624,864109,825May 24 04:15 PM
Bailey John E. (Jack) Jr.President and CEOMay 13 '24Sale4.7937,258178,421452,336May 15 04:06 PM
MURDOCK TERRY LChief Operating OfficerMay 13 '24Sale4.798,15139,03495,487May 15 04:10 PM
Umstead John W. VChief Financial OfficerMay 13 '24Sale4.798,15139,034153,245May 15 04:11 PM
Malik RajeshChief Medical OfficerMay 13 '24Sale4.798,15139,034161,787May 15 04:08 PM
Avagliano MarkChief Business OfficerMay 13 '24Sale4.798,15139,034209,683May 15 04:07 PM
Umstead John W. VChief Financial OfficerMar 18 '24Sale3.026,54719,752123,896Mar 20 04:32 PM
Malik RajeshChief Medical OfficerFeb 12 '24Option Exercise0.3028,6008,580198,538Feb 13 06:14 PM
Malik RajeshChief Medical OfficerFeb 12 '24Sale4.6228,600132,143169,938Feb 13 06:14 PM
MURDOCK TERRY LChief Operating OfficerJan 04 '24Sale2.947212,121103,638Jan 08 06:00 AM
Avagliano MarkChief Business OfficerJan 04 '24Sale2.947212,121117,834Jan 08 06:02 AM
Malik RajeshChief Medical OfficerJan 04 '24Sale2.947212,121169,938Jan 08 06:03 AM
Umstead John W. VChief Financial OfficerJan 04 '24Sale2.94111327130,443Jan 08 06:04 AM
Bailey John E. (Jack) Jr.President and CEOJan 03 '24Sale3.1211,68636,447489,594Jan 08 06:02 AM
Avagliano MarkChief Business OfficerJan 03 '24Sale3.123,36010,480118,555Jan 08 06:02 AM
MURDOCK TERRY LChief Operating OfficerJan 03 '24Sale3.123,0199,416104,359Jan 08 06:00 AM
Malik RajeshChief Medical OfficerJan 03 '24Sale3.123,0199,416170,659Jan 08 06:03 AM
Perry AndrewChief Commercial OfficerJan 03 '24Sale3.122,4137,52687,102Jan 08 06:03 AM
Umstead John W. VChief Financial OfficerJan 03 '24Sale3.126321,971130,554Jan 08 06:04 AM
Bailey John E. (Jack) Jr.President and CEOJan 02 '24Sale3.2732,983108,006400,580Jan 02 07:44 PM
Malik RajeshChief Medical OfficerDec 11 '23Option Exercise0.3633,83912,081157,817Dec 13 04:45 PM
Malik RajeshChief Medical OfficerDec 11 '23Sale3.4133,839115,522136,378Dec 13 04:45 PM
Velleca Mark A.DirectorAug 08 '23Option Exercise0.3960,00023,156173,286Aug 10 04:11 PM
Velleca Mark A.DirectorAug 08 '23Sale2.0060,000119,974116,000Aug 10 04:11 PM
Bailey John E. (Jack) Jr.President and CEOJul 05 '23Sale2.452,7196,672433,563Jul 07 04:07 PM
MURDOCK TERRY LChief Operating OfficerJul 05 '23Sale2.451,3613,33970,078Jul 07 04:08 PM
Malik RajeshChief Medical OfficerJul 05 '23Sale2.451,3613,339136,378Jul 07 04:08 PM
Perry AndrewChief Commercial OfficerJul 05 '23Sale2.4535587155,945Jul 07 04:08 PM